PDCD1 and neoplasm: CD64-positive (CD64+) Mφ exhibit an increased phagocytosis ability [22], which has been reported to be associated with blocking the anti-tumor effect of anti-PD-1 antibodies in mouse models through ADCP-mediated T-cell elimination [23].